 |
Saïd M. Sebti, Ph.D. Associate Director, Moffitt Research Institute Program Leader, Drug Discovery Professor in the Interdisciplinary Oncology Program Member-in-Residence of the Moffitt Cancer Center E-mail:Said.Sebti@moffitt.org |
Training
B.S.: Washington State University, Pullman, WA, 1980.
Ph.D.: Purdue University, W. Lafayette, IN, 1984.
Postdoctoral Fellowship: Yale University, New Haven, CT, 1985-1987.
Research Interests
Dr. Sebti's research interests are as follows: 1)To understand the mechanism by which normal cells become cancerous with a focus on aberrant signal transduction; 2) To develop novel anticancer drugs based on targeting growth factor signal transduction, cell cycle, angiogenesis and apoptosis pathways. Of particular interest is the role of Ras protein in receptor tyrosine kinase signal transduction; key molecules that are presently targeted are farnesyltransferase, geranylgeranyltransferase, STAT3, VEGF, EGF and PDGF and their receptors, proteasome, cyclin-dependent kinases, Bcl2, Mek and Akt; and 3) To understand the mechanism by which the GTPase RhoB suppresses tumor growth, angiogenesis and metastasis.
Search
for publications by: 
This
search will be conducted at the US National Library of Medicine (NLM) and PubMed.
Selected Publications
Jiang, K, Sun, J, Cheng J, Djeu JY, Wei S and Sebti, S.M. Akt mediates Ras downregulation of RhoB, a suppressor of transformation, invasion and metastasis. Mol. Cell. Biol. 24: 5565-76, 2004.
Alsina, M., Fonseca, R., Wilson, E.F., Belle, N., Gerbino, E., Price-Troska, T., Overton, R., Ahmann, G., Bruzek, L., Adjei, A., Kaufmann, S., Wright, J.J., Sullivan, D., Djulbegovic, B., Cantor, A.B., Greipp, P.R., Dalton, W.S. and Sebti, S.M. Farnesyltransferase Inhibitor FTI-R115777 is well tolerated, induces stabilization of disease and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma. Blood 103: 3271-3277, 2004.
Sun, J.; Wang, De-An; Jain, R.; Paquette, S.; Ennis, Eileen; Blaskovich, Michelle; Baldini, L.; Coppola, D.; Hamilton, A.; Sebti, S.M. Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene. (In Press)
Sun, J., Ohkanda, J., Coppola, D., Yin, H., Kothare, M., Busciglio, B., Hamilton, A.D. and Sebti, S.M. Geranylgeranyltransferase Inhibitor, GGTI-2154, Induces Breast Carcinoma Apoptosis and Tumor Regression in Ras Transgenic Mice. Cancer Res 63: 8922-8929, 2003.
Yang, L., Dan, H.C., Sun, M., Liu, Q., Sun, X-M, Feldman, R. I., Hamilton, A.D., Polokoff, M., Nicosia, S.V., Herlyn, M., Sebti, S.M., Cheng, J.Q. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor acitivity in cancer cells overexpressing Akt. Cancer Res 64: 4394-9, 2004.
Blaskovich, M.A., Sun, J., Turkson, J., Jove, R. and Sebti, S.M. Discovery of JSI-124, a selective JAK/STAT3 signaling pathway inhibitor with potent antitumor activity against human cancer cells in nude mice. Cancer Research 63(6): 1270-9, 2003.
Cancer Biology Ph.D. Program
H. Lee Moffitt Cancer Center, MRC-4 East
12902 Magnolia Drive
Tampa, Florida 33612
Phone: 813-745-6876
E-mail: CancerPHD@moffitt.org
Copyright © 2000 University of South Florida